ProShares Ultra NASDAQ Biotechnology
30 hedge funds and large institutions have $18.6M invested in ProShares Ultra NASDAQ Biotechnology in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0.28% less ownership
Funds ownership: 9.29% → 9.01% (-0.28%)
6% less capital invested
Capital invested by funds: $19.7M → $18.6M (-$1.08M)
Holders
30
Holding in Top 10
–
Calls
$7.58M
Puts
$6.62M
Top Buyers
| 1 | +$3.5M | |
| 2 | +$2.09M | |
| 3 | +$1.78M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.3M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$809K |
Top Sellers
| 1 | -$8.54M | |
| 2 | -$690K | |
| 3 | -$355K | |
| 4 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$231K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$43.3K |